MAIA

Price & events

Pipeline stages · 1 programs

Pipeline · 2 trials · 2 upcoming

Catalyst news & presentations · 11

• next yearGuided 40%readoutPhase 3ateganosine · Interim data from Phase 3 THIO-104 trial expected to support FDA discussion.SEC 8-K
• 2026Guided 40%trial initiationsecondaryPhase 2ateganosine · Intends to open four additional US sites for THIO-101 expansion trialSEC 8-K
• 2026Guided 40%readoutPhase 3ateganosine · Initial measures of efficacy (DCR, ORR, PFS) from Phase 3 studySEC 8-K
• 2026Guided 40%trial initiationsecondaryPhase 1second-generation telomere-targeting agents · Clinical development of second-generation molecules to start in Phase 1 trialsSEC 8-K
• 2026-04-08partnershipateganosine · $33 million public offering completed in March 2026 to fund Phase 3 trial.SEC 8-K
• March 27, 2026conferencedata presentationsecondaryAteganosine · Poster presented at ELCC 2026 on sustained response and long-term benefits of ateganosine plus ICI in THIO-101 trial.SEC 8-K
• January 13, 2026conferencedata presentationsecondaryBiotech Showcase presentationSEC 8-K
• By the end of this yeartrial initiationsecondaryPhase 2ateganosine · Expect to have all required approvals to begin enrolling patients in a HCC trialSEC 8-K
• November 10, 2025conferencedata presentationsecondaryPhase 2ateganosine (THIO) · THIO-101 Phase 2 trial in progress poster presented at SITC 2025SEC 8-K
• July 9, 2025trial initiationsecondaryPhase 2ateganosine · First patient dosed in expansion of Phase 2 trial THIO-101.SEC 8-K
• 2025-06-18partnershipateganosine · Master Clinical Supply Agreement with Roche for combination with atezolizumabSEC 8-K